<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumors</z:e>, the platelet-derived growth factor receptor B (PDGFRB) is mainly expressed by stromal cells of mesenchymal origin </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> cells may also acquire PDGFRB expression following epithelial-to-mesenchymal transition (EMT), which occurs during <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> formation </plain></SENT>
<SENT sid="2" pm="."><plain>Little is known about PDGFRB signaling in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>We studied the relationship between PDGFRB expression, EMT, and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cohorts by analysis of gene expression profiles </plain></SENT>
<SENT sid="4" pm="."><plain>PDGFRB expression in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was correlated with short disease-free and overall survival </plain></SENT>
<SENT sid="5" pm="."><plain>PDGFRB was co-expressed with genes involved in platelet activation, transforming growth factor beta (TGFB) signaling, and EMT in three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cohorts </plain></SENT>
<SENT sid="6" pm="."><plain>PDGFRB was expressed in mesenchymal-like <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines in vitro and stimulated invasion and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> formation in mice </plain></SENT>
<SENT sid="7" pm="."><plain>Platelets, a major source of PDGF, preferentially bound to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in a non-activated state </plain></SENT>
<SENT sid="8" pm="."><plain>Platelet activation caused robust PDGFRB tyrosine phosphorylation on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in vitro and in liver sinusoids in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>Platelets also release TGFB, which is a potent inducer of EMT </plain></SENT>
<SENT sid="10" pm="."><plain>Inhibition of TGFB signaling in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells caused partial reversion of the mesenchymal phenotype and strongly reduced PDGFRB expression and PDGF-stimulated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell invasion </plain></SENT>
<SENT sid="11" pm="."><plain>These results suggest that PDGFRB may contribute to the aggressive phenotype of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> with mesenchymal properties, most likely downstream of platelet activation and TGFB signaling </plain></SENT>
</text></document>